Byetta Can Now Officially Be Used With Lantus

written by Michael O'Leary

Adult type 2 diabetes patients who use insulin have a new option for controlling their blood glucose.

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company announced Oct. 19, that the FDA has approved a new use for BYETTA® (exenatide) injection. The drug can now be used by those using the insulin glargine (Lantus®) with or without metformin and or thiazolidinedione and still haven’t achieved control of their blood sugar.

Dr. Christian Weyer, senior vice president, research and development at Amylin said this marks an important new option for the 60 percent of type 2 diabetes patients who haven’t been able to reach their target blood sugar levels. (Link to published site)

Is Victoza Better Than Bydureon?

September 22nd, 2011 by Ryan Luce No Comments

written by Michael O’Leary

Daily injections of liraglutide (Victoza) nosed out once-a-week injections of exenatide (Bydureon) in a head-to-head comparison in terms of reducing HbA1c, but type 2 diabetes patients using exenatide experienced fewer, milder side effects.

The results of the clinical trial were presented last week at the 47^th Annual meeting of the European Association for the Study of Diabetes last week in Lisbon, Portugal and was reported on by MedPage Today. (Link to published site)